SCYNEXIS INC (SCYX) Stock Fundamental Analysis

NASDAQ:SCYX • US8112922005

0.79 USD
+0.01 (+0.77%)
Last: Feb 23, 2026, 01:48 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, SCYX scores 3 out of 10 in our fundamental rating. SCYX was compared to 192 industry peers in the Pharmaceuticals industry. While SCYX seems to be doing ok healthwise, there are quite some concerns on its profitability. SCYX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • SCYX had negative earnings in the past year.
  • In the past year SCYX has reported a negative cash flow from operations.
  • SCYX had negative earnings in 4 of the past 5 years.
  • In the past 5 years SCYX reported 4 times negative operating cash flow.
SCYX Yearly Net Income VS EBIT VS OCF VS FCFSCYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • SCYX has a worse Return On Assets (-49.54%) than 60.94% of its industry peers.
  • SCYX has a Return On Equity (-69.45%) which is in line with its industry peers.
Industry RankSector Rank
ROA -49.54%
ROE -69.45%
ROIC N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
SCYX Yearly ROA, ROE, ROICSCYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • With an excellent Gross Margin value of 127.76%, SCYX belongs to the best of the industry, outperforming 98.44% of the companies in the same industry.
  • SCYX's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SCYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 127.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
SCYX Yearly Profit, Operating, Gross MarginsSCYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SCYX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, SCYX has more shares outstanding
  • The debt/assets ratio for SCYX is higher compared to a year ago.
SCYX Yearly Shares OutstandingSCYX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SCYX Yearly Total Debt VS Total AssetsSCYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -10.78, we must say that SCYX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -10.78, SCYX is doing worse than 70.31% of the companies in the same industry.
  • There is no outstanding debt for SCYX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.78
ROIC/WACCN/A
WACC9.27%
SCYX Yearly LT Debt VS Equity VS FCFSCYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

  • SCYX has a Current Ratio of 5.75. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
  • SCYX has a better Current ratio (5.75) than 67.19% of its industry peers.
  • A Quick Ratio of 5.75 indicates that SCYX has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 5.75, SCYX is doing good in the industry, outperforming 68.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.75
Quick Ratio 5.75
SCYX Yearly Current Assets VS Current LiabilitesSCYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • SCYX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.08%, which is quite impressive.
  • Looking at the last year, SCYX shows a very negative growth in Revenue. The Revenue has decreased by -65.77% in the last year.
  • The Revenue has been growing by 99.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)31.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.33%
Revenue 1Y (TTM)-65.77%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%-49.39%

3.2 Future

  • Based on estimates for the next years, SCYX will show a small growth in Earnings Per Share. The EPS will grow by 3.11% on average per year.
  • SCYX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.60% yearly.
EPS Next Y13.07%
EPS Next 2Y36.7%
EPS Next 3Y-0.41%
EPS Next 5Y3.11%
Revenue Next Year-23.26%
Revenue Next 2Y72.19%
Revenue Next 3Y-39.59%
Revenue Next 5Y1.6%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SCYX Yearly Revenue VS EstimatesSCYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
SCYX Yearly EPS VS EstimatesSCYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • SCYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SCYX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCYX Price Earnings VS Forward Price EarningsSCYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCYX Per share dataSCYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.7%
EPS Next 3Y-0.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SCYX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SCYNEXIS INC

NASDAQ:SCYX (2/23/2026, 1:48:08 PM)

0.79

+0.01 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)03-10
Inst Owners28.09%
Inst Owner Change-23.3%
Ins Owners2.16%
Ins Owner Change12.33%
Market Cap33.16M
Revenue(TTM)2.93M
Net Income(TTM)-25.30M
Analysts84.44
Price Target3.74 (373.42%)
Short Float %2.78%
Short Ratio2.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.21%
Min EPS beat(2)16.67%
Max EPS beat(2)27.76%
EPS beat(4)4
Avg EPS beat(4)35.67%
Min EPS beat(4)16.67%
Max EPS beat(4)59.89%
EPS beat(8)6
Avg EPS beat(8)16.42%
EPS beat(12)9
Avg EPS beat(12)10.62%
EPS beat(16)11
Avg EPS beat(16)12.39%
Revenue beat(2)2
Avg Revenue beat(2)445.05%
Min Revenue beat(2)121.75%
Max Revenue beat(2)768.35%
Revenue beat(4)3
Avg Revenue beat(4)205.53%
Min Revenue beat(4)-90.6%
Max Revenue beat(4)768.35%
Revenue beat(8)6
Avg Revenue beat(8)194.61%
Revenue beat(12)9
Avg Revenue beat(12)128.92%
Revenue beat(16)9
Avg Revenue beat(16)88.28%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.75%
EPS NY rev (1m)0%
EPS NY rev (3m)5.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-47.52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-42.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.31
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.07
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.54%
ROE -69.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 127.76%
FCFM N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.75
Quick Ratio 5.75
Altman-Z -10.78
F-Score3
WACC9.27%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.33%
EPS Next Y13.07%
EPS Next 2Y36.7%
EPS Next 3Y-0.41%
EPS Next 5Y3.11%
Revenue 1Y (TTM)-65.77%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%-49.39%
Revenue Next Year-23.26%
Revenue Next 2Y72.19%
Revenue Next 3Y-39.59%
Revenue Next 5Y1.6%
EBIT growth 1Y33.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-174.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-174.5%
OCF growth 3YN/A
OCF growth 5YN/A

SCYNEXIS INC / SCYX FAQ

Can you provide the ChartMill fundamental rating for SCYNEXIS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SCYX.


What is the valuation status for SCYX stock?

ChartMill assigns a valuation rating of 0 / 10 to SCYNEXIS INC (SCYX). This can be considered as Overvalued.


What is the profitability of SCYX stock?

SCYNEXIS INC (SCYX) has a profitability rating of 1 / 10.